ENHERTU® trastuzumab deruxtecan
ENHERTU® als monotherapie is geïndiceerd voor de behandeling van volwassen patiënten met nietreseceerbare of gemetastaseerde HER2-positieve borstkanker die voorafgaand één of meerbehandelschema’s op basis van anti-HER2-therapieën hebben gekregen.
Andere ENHERTU® hulpmiddelen
Podcasts
Trastuzumab Deruxtecan ILD by Prof. Jerusalem & Prof. Duhoux
Trastuzumab Deruxtecan Other Adverse Effects by Prof. Jerusalem, Prof. Duhoux & Dr Aftimos
Trastuzumab Deruxtecan Nausea and vomiting by Prof. Jerusalem & Dr Aftimos
BJMO Highlights of 2022 SABCS by Dr Aftimos
Video
Trastuzumab Deruxtecan Nausea and vomiting by Prof. Jerusalem & Dr Aftimos
Trastuzumab Deruxtecan ILD by Prof. Jerusalem & Prof. Duhoux
Trastuzumab Deruxtecan Other Adverse Effects by Prof. Jerusalem, Prof. Duhoux & Dr Aftimos
Dr. Duhem answers questions on ADC sequencing, practical aspects when treating with ADCs and how to optimize treatment with ENHERTU®
Documenten
Optimizing treatment management of Trastuzumab Deruxtecan by Prof Jerusalem & Prof. Wildiers 2022 BJMO
Belgian clinical guidelines for HER2-postivie advanced breast cancer 2022 BJMO
Article Cancer du sein métastatique HER2+ : le T-Dxd fortement recommandé par l'ESMO et la BSMO par Prof. Duhoux
ILD & Pneumonitis management Dr Duhoux Dr Naert
Nausea & vomiting management Dr Aftimos Prof Wildiers